Drug Profile
Influenza vaccine quadrivalent - China National Biotec Group
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator China National Biotec Group
- Developer Changchun Institute of Biological Products; China National Biotec Group
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 01 Dec 2015 Launched for Influenza virus infections (Prevention) in China prior to December 2015
- 01 Dec 2015 Changchun Institute of Biological Products initiates enrolment in a phase IV trial for Influenza virus infections (In Infants, In children, In adolescents) in China (ChiCTR-PPR-15007470)